Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations

Hepcidin regulation is linked to both iron and inflammatory signals and may influence iron loading in nonalcoholic steatohepatitis (NASH). The aim of this study was to examine the relationships among HFE genotype, serum hepcidin level, hepatic iron deposition, and histology in nonalcoholic fatty liver disease (NAFLD). Single‐nucleotide polymorphism genotyping for C282Y (rs1800562) and H63D (rs1799945) HFE mutations was performed in 786 adult subjects in the NASH Clinical Research Network (CRN). Clinical, histologic, and laboratory data were compared using nonparametric statistics and multivariate logistic regression. NAFLD patients with C282Y, but not H63D mutations, had lower median serum hepcidin levels (57 versus 65 ng/mL; P = 0.01) and higher mean hepatocellular (HC) iron grades (0.59 versus 0.28; P < 0.001), compared to wild‐type (WT) subjects. Subjects with hepatic iron deposition had higher serum hepcidin levels than subjects without iron for all HFE genotypes (P < 0.0001). Hepcidin levels were highest among patients with mixed HC/reticuloendothelial system cell (RES) iron deposition. H63D mutations were associated with higher steatosis grades and NAFLD activity scores (odds ratio [OR], ≥1.4; 95% confidence interval [CI]: >1.0, ≤2.5; P ≤ 0.041), compared to WT, but not with either HC or RES iron. NAFLD patients with C282Y mutations had less ballooning or NASH (OR, ≤0.62; 95% CI: >0.39, <0.94; P ≤ 0.024), compared to WT subjects. Conclusions: The presence of C282Y mutations in patients with NAFLD is associated with greater HC iron deposition and decreased serum hepcidin levels, and there is a positive relationship between hepatic iron stores and serum hepcidin level across all HFE genotypes. These data suggest that body iron stores are the major determinant of hepcidin regulation in NAFLD, regardless of HFE genotype. A potential role for H63D mutations in NAFLD pathogenesis is possible through iron‐independent mechanisms. (HEPATOLOGY 2012;56:1730–1740)

[1]  F. Brancati,et al.  Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. , 2011, Journal of hepatology.

[2]  L. Fletcher,et al.  Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[3]  Y. Yılmaz,et al.  Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. , 2011, Metabolic syndrome and related disorders.

[4]  Jonathan C. Cohen,et al.  Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.

[5]  P. Galle,et al.  Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. , 2011, European journal of internal medicine.

[6]  James E. Nelson,et al.  Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease , 2011, Hepatology.

[7]  E. Galmozzi,et al.  Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. , 2010, Journal of hepatology.

[8]  B. Neuschwander‐Tetri,et al.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.

[9]  Nayoung Kim,et al.  Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease , 2010, The Korean journal of hepatology.

[10]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[11]  G. Marchesini,et al.  HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[12]  D. Swinkels,et al.  Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[13]  H. Tsukamoto,et al.  Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. , 2009, Cell metabolism.

[14]  D. Girelli,et al.  Immunoassay for human serum hepcidin. , 2008, Blood.

[15]  P. Castellino,et al.  The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations , 2008, Internal medicine journal (Print).

[16]  N. Andrews,et al.  The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. , 2008, Cell metabolism.

[17]  D. English,et al.  Iron-overload-related disease in HFE hereditary hemochromatosis. , 2008, The New England journal of medicine.

[18]  S. Cotler,et al.  Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. , 2008, World journal of gastroenterology.

[19]  James E. Nelson,et al.  HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis , 2007, Hepatology.

[20]  R. Ceriani,et al.  α1‐Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage , 2006, Hepatology.

[21]  N. Andrews,et al.  Hereditary Hemochromatosis Protein, HFE, Interaction with Transferrin Receptor 2 Suggests a Molecular Mechanism for Mammalian Iron Sensing* , 2006, Journal of Biological Chemistry.

[22]  Y. Jiang,et al.  Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2–ASK1 signals , 2006, Oncogene.

[23]  E. Harris,et al.  Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force , 2006, Annals of Internal Medicine.

[24]  C. Bica,et al.  Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis. , 2006, Arquivos de gastroenterologia.

[25]  C. Deng,et al.  A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. , 2005, Cell metabolism.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[27]  B. Grant,et al.  Effectiveness of the derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. , 2005, Alcoholism, clinical and experimental research.

[28]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[29]  Hong Liu,et al.  Protein Profiling of Mouse Livers with Peroxisome Proliferator-Activated Receptor α Activation , 2004, Molecular and Cellular Biology.

[30]  A. Lonardo,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[31]  M. Redinbo,et al.  Human carboxylesterase 1: from drug metabolism to drug discovery. , 2003, Biochemical Society transactions.

[32]  A. Laudanna,et al.  Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  H. Bonkovsky,et al.  Iron as a co-morbid factor in nonhemochromatotic liver disease. , 2003, Alcohol.

[34]  E. Taioli,et al.  Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[35]  D. Purdie,et al.  Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis , 2003, The Lancet.

[36]  M. Weltman,et al.  HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity , 2002, Hepatology.

[37]  L. N. Valenti,et al.  Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.

[38]  N. Andrews,et al.  Genes that modify the hemochromatosis phenotype in mice. , 2000, The Journal of clinical investigation.

[39]  H. Bonkovsky,et al.  Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[40]  P. Ward,et al.  Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.

[41]  C. Vulpe,et al.  Iron-independent specific protein expression pattern in the liver of HFE-deficient mice. , 2007, The international journal of biochemistry & cell biology.

[42]  Hong Liu,et al.  Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. , 2004, Molecular and cellular biology.

[43]  D. Girelli,et al.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.

[44]  Thomas T. Pace.  California Pacific Medical Center , 1992 .